Search research articles
Contact Us
Filters
Showing results (51-60 of 82) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Cancer
|
November 2, 2006
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study
Alice B Kornblith, Jeannette M Dowell, James E Herndon, et al.
The Oncologist
|
August 19, 2024
Treatment of Acute Myeloid Leukemia in the Community Setting
Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M Habermann, Edie A Weller, Vicki A Morrison, et al.
Vaccine
|
December 3, 2014
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age
Xiaoming Li, Jane H Zhang, Robert F Betts, et al.
Leukemia & Lymphoma
|
February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study
Gerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 82) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 16, 2011
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712
Jennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 14, 2002
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011
Vicki A Morrison, Kanti R Rai, Bercedis L Peterson, et al.
Blood
|
May 13, 2004
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
John C Byrd, Kanti Rai, Bercedis L Peterson, et al.
Cancer
|
November 2, 2006
Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study
Alice B Kornblith, Jeannette M Dowell, James E Herndon, et al.
The Oncologist
|
August 19, 2024
Treatment of Acute Myeloid Leukemia in the Community Setting
Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 7, 2006
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M Habermann, Edie A Weller, Vicki A Morrison, et al.
Vaccine
|
December 3, 2014
Modeling the durability of ZOSTAVAX® vaccine efficacy in people ≥60 years of age
Xiaoming Li, Jane H Zhang, Robert F Betts, et al.
Leukemia & Lymphoma
|
February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study
Gerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 13, 2012
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies
Jennifer A Woyach, Amy S Ruppert, Kanti Rai, et al.
Cancer Chemotherapy and Pharmacology
|
July 12, 2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study
Robert E Martell, Bercedis L Peterson, Harvey Jay Cohen, et al.
Page
of 9